Safinamide improves motor symptoms in PD
German-Swiss drugmaker Merck Serono says that Phase III data from trials of the developmental Parkinson's disease treatment safinamide demonstrate that addition of the drug to a stable-dose dopamine agonist improved motor symptoms in patients suffering from early-stage disease.
The trial, which examined the effect of adding one of two daily doses of the drug, either 50mg or 100mg, to a dopamine agonist, revealed that the combined regimen boosted Unified Parkinson's Disease Rating scores to between 6.0 and 7.2, compared with 3.6 to 7.1 in the dopamine mono-therapy group. The drug, licensed from Italy's Newron, is currently being assessed in a Phase III extension study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze